Multiple Sclerosis: Is Therapeutic Angiogenesis a Treatment or Even a Possible Cure?
November 18, 2020 00:00 ET
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announced that it will give a Webinar broadcast on its potential breakthrough therapy to...
AB Science sécurise avec Alpha Blue Ocean un financement optionnel en fonds propres sous la forme d'un PACT dans la limite de 4 millions d'actions
November 16, 2020 02:17 ET
|
AB Science
NE DOIT PAS ETRE DISTRIBUE OU PUBLIE, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS D’AMERIQUE, AU CANADA, EN AUSTRALIE OU AU JAPON Paris, 16 novembre 2020, 8h30 ...
AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
November 16, 2020 02:17 ET
|
AB Science
NOT FOR DISTRIBUTION, PUBLICATION, RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN Paris, November 16, 2020, 8:30 am AB SCIENCE SECURES EQUITY...
ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions
October 16, 2020 05:25 ET
|
ASLAN PHARMACEUTICALS LIMITED
-- ASLAN believes ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH...
Insights on the Auto-Injectors Global Market to 2026 - Featuring Antares Pharma, Mylan & Amgen Among Others
October 01, 2020 04:59 ET
|
Research and Markets
Dublin, Oct. 01, 2020 (GLOBE NEWSWIRE) -- The "Auto-Injectors Market Global Forecast by Regions, Application (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Others), Product Types,...
AB Science dévoile les résultats de son étude de Phase IIB/III dans les formes progressives de la Sclérose en Plaques à l’occasion du plus grand congrès international sur la sclérose en plaques
September 14, 2020 00:58 ET
|
AB Science
Paris, 14 septembre 2020, 7h00 Communiqué de Presse AB Science dévoile les résultats de son étude de Phase IIB/III dans les formes progressives de la Sclérose en Plaques à l’occasion du plus grand...
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference
September 14, 2020 00:58 ET
|
AB Science
Paris, September 14, 2020, 7am Press release AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference 50% of...
AB Science présentera les résultats de son étude de phase 2B/3 AB07002 dans les formes progressives de la sclérose en plaques à la 8ème réunion conjointe ACTRIMS-ECTRIMS (MSVirtual2020)
September 07, 2020 01:30 ET
|
AB Science
Paris, 7 septembre 2020, 7h30 AB Science présentera les résultats de son étude de phase 2B/3 AB07002dans les formes progressives de la sclérose en plaques à la 8ème réunion conjointe ACTRIMS-ECTRIMS...
AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
September 07, 2020 01:30 ET
|
AB Science
Paris, September 07, 2020, 7.30am AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting ...
AB Science announces that new results published in the peer-reviewed Journal of Alzheimer's Disease support masitinib’s potential mode of action in Alzheimer’s Disease
July 08, 2020 02:57 ET
|
AB Science
Paris, 08 July 2020, 9am New results published in the peer-reviewed Journal of Alzheimer's Diseasesupport masitinib’s potential mode of action in Alzheimer’s Disease ...